Abbvie patents expiration
1. Androgel patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8741881 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
| US8729057 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
| US8466137 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
| US8466138 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
| US8466136 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
| US8759329 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
| US8486925 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
| US8754070 | ABBVIE | Testosterone gel and method of use |
Oct, 2026
(3 years from now) | |
Drugs and Companies using TESTOSTERONE ingredient
Market Authorisation Date: 29 April, 2011
Treatment: Testosterone replacement therapy in males for conditions associated with a deficiency or absence of endogenous testosterone
Dosage: GEL, METERED;TRANSDERMAL; GEL;TRANSDERMAL
ANDROGEL family patents
2. Oriahnn (copackaged) patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11542239 | ABBVIE | Elagolix sodium compositions and processes |
Jul, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11690845 | ABBVIE | Methods of administering elagolix |
Aug, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
| New Product (NP) | May 29, 2023 |
NCE-1 date: 2022-07-23
Market Authorisation Date: 29 May, 2020
Treatment: Management of heavy menstrual bleeding associated with uterine leiomyomas (fibroids) using 300 mg elagolix while co-administering omeprazole
Dosage: CAPSULE;ORAL
ORIAHNN (COPACKAGED) family patents
3. Orilissa patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11542239 | ABBVIE | Elagolix sodium compositions and processes |
Jul, 2039
(15 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11707464 | ABBVIE | Methods of treating heavy menstrual bleeding |
Mar, 2034
(10 years from now) | |
| US11690854 | ABBVIE | Methods of treating heavy menstrual bleeding |
Apr, 2038
(14 years from now) | |
| US11690845 | ABBVIE | Methods of administering elagolix |
Aug, 2040
(16 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Jul 23, 2023 |
Drugs and Companies using ELAGOLIX SODIUM ingredient
NCE-1 date: 2022-07-23
Market Authorisation Date: 23 July, 2018
Treatment: Management of moderate to severe pain associated with endometriosis using 150 mg elagolix for up to 24 months; Management of moderate to severe pain associated with endometriosis in a patient with mod...
Dosage: TABLET;ORAL
ORILISSA family patents
4. Rinvoq patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11661425 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US11680069 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US11718627 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11524964 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US11535624 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-α]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US11535625 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US11535626 | ABBVIE | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1 carboxamide and solid state forms thereof |
Oct, 2036
(13 years from now) | |
| US11564922 | ABBVIE | Methods of treating crohn's disease and ulcerative colitis |
Mar, 2038
(14 years from now) | |
| US11607411 | ABBVIE | Methods of treating Crohn's disease and ulcerative colitis |
Mar, 2038
(14 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Aug 16, 2024 |
| New Indication (I) | Jan 14, 2025 |
Drugs and Companies using UPADACITINIB ingredient
NCE-1 date: 2023-08-17
Market Authorisation Date: 16 August, 2019
Treatment: Treatment of adults with active ankylosing spondylitis who have had an inadequate response or intolerance to one or more tnf blockers; Treatment of adults with moderately to severely active rheumatoid...
Dosage: TABLET, EXTENDED RELEASE;ORAL
RINVOQ family patents
5. Tricor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7276249 | ABBVIE | Nanoparticulate fibrate formulations |
Feb, 2023
(7 months ago) | |
| US7320802 | ABBVIE | Methods of treatment using nanoparticulate fenofibrate compositions |
Feb, 2023
(7 months ago) | |
Drugs and Companies using FENOFIBRATE ingredient
Market Authorisation Date: 05 November, 2004
Treatment: Adjunctive therapy to diet in adults to reduce ldl-c, triglycerides and apo b, and increase hdl-c in patients with primary hypercholesterolemia or mixed dyslipidemia (types iia, iib) and to treat hype...
Dosage: TABLET;ORAL
TRICOR family patents
6. Trilipix patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7259186 | ABBVIE | Salts of fenofibric acid and pharmaceutical formulations thereof |
Jan, 2025
(1 year, 3 months from now) | |
Drugs and Companies using CHOLINE FENOFIBRATE ingredient
Market Authorisation Date: 15 December, 2008
Treatment: NA
Dosage: CAPSULE, DELAYED RELEASE;ORAL
TRILIPIX family patents
7. Venclexta patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11590128 | ABBVIE | Combination therapy of a type II anti-CD20 antibody with a selective BCL-2 inhibitor |
Sep, 2033
(9 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | May 15, 2026 |
| M (M) | Oct 16, 2023 |
Drugs and Companies using VENETOCLAX ingredient
Market Authorisation Date: 11 April, 2016
Treatment: Treatment of aml by orally administering venetoclax with azacitidine or decitabine or low-dose cytarabine to adults 75 years or older or having certain comorbidities per a dose ramp-up including an in...
Dosage: TABLET;ORAL
VENCLEXTA family patents
8. Vraylar patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| USRE49302 | ABBVIE | Pharmaceutical formulations containing dopamine receptor ligands |
Jul, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Indication (I) | Dec 16, 2025 |
Drugs and Companies using CARIPRAZINE HYDROCHLORIDE ingredient
Market Authorisation Date: 17 September, 2015
Treatment: Treatment of schizophrenia with cariprazine; Adjunctive therapy to antidepressants for the treatment of major depressive disorder; Treatment of acute manic or mixed episodes associated with bipolar i ...
Dosage: CAPSULE;ORAL
VRAYLAR family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic